T1	Participants 72 254	140 patients with a threatening premature birth at the greater than or equal to 24-less than 37 week of gestation were in this study randomly treated with hexoprenalin or salbutamol.
T2	Participants 258 379	77% in the hexoprenalin and in 74% in the salbutamol group the weight of the newborn was greater than or equal to 2500 g.
T3	Participants 383 469	66% in both study groups the birth occurred after the completed 37 weeks of gestation.
T4	Participants 598 715	11% of the mothers in the hexoprenalin group had side-effects during infusion compared to 30% in the salbutamol group
